𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pegylated Interferon and Ribavirin for the Recurrence of Chronic Hepatitis C Genotype 1 in Transplant Patients

✍ Scribed by E. Oton; R. Barcena; S. Garcia-Garzon; A. Moreno-Zamora; A. Moreno; M. Garcia-Gonzalez; C. Blesa; J.R. Foruny; P. Ruiz

Book ID
116931819
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
49 KB
Volume
37
Category
Article
ISSN
0041-1345

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
✍ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 240 KB πŸ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a

Pegylated interferon and ribavirin thera
Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection
✍ F. Legrand-Abravanel; F. Nicot; A. Boulestin; K. Sandres-SaunΓ©; J.P. Vinel; L. A πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 91 KB

## Abstract Hepatitis C Virus (HCV) is classified into six genotypes. Genotype 4 is now spreading in Europe, especially among drug users, who are often infected with both HCV and the human immunodeficiency virus (HIV). Previous studies have shown that HCV‐4 responds poorly to interferon. Pegylated